Xilio Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference
September 22 2022 - 3:05PM
Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company
developing tumor-selective immuno-oncology therapies for people
living with cancer, today announced that the company will
participate in a fireside chat at the Guggenheim Nantucket
Therapeutics Conference on Thursday, September 29, 2022, at 10:15
a.m. ET.
A live webcast of the presentation can be accessed under “Events
& Presentations” in the Investors & Media section of the
Xilio Therapeutics website at https://ir.xiliotx.com/. A replay of
the webcast will be archived on the website for 30 days following
the presentation.
About Xilio Therapeutics
Xilio Therapeutics is a clinical-stage biotechnology company
focused on harnessing the immune system to achieve deep and durable
clinical responses to improve the lives of patients with cancer.
The company is using its proprietary geographically precise
solutions (GPS) platform to rapidly engineer novel molecules,
including cytokines and other biologics, that are designed to
optimize their therapeutic index. These molecules are designed to
localize activity within the tumor microenvironment without
systemic effects, resulting in the potential to achieve enhanced
anti-tumor activity. Xilio is building a pipeline of wholly owned,
tumor-selective, GPS-enabled cytokine and checkpoint inhibitor
product candidates, including its clinical-stage programs, XTX101,
a tumor-selective anti-CTLA-4 monoclonal antibody, and XTX202, a
tumor-selective IL-2, as well as its earlier pipeline, including
XTX301, a tumor-selective IL-12. For more information, please
visit https://xiliotx.com and follow us on
Twitter (@xiliotx) and LinkedIn (Xilio Therapeutics,
Inc.).
For Investor Inquiries:Myles CloustonVice
President, Investor Relationsinvestors@xiliotx.com
For Media Inquiries: Julissa VianaVice
President, Corporate Communicationsmedia@xiliotx.com
Xilio Therapeutics (NASDAQ:XLO)
Historical Stock Chart
From Apr 2024 to May 2024
Xilio Therapeutics (NASDAQ:XLO)
Historical Stock Chart
From May 2023 to May 2024